360° SearchNetwork Hot Spots Trends Time Series

ImmunoCellular Therapeutics

Type: Company

Name: ImmunoCellular Therapeutics

First reported May 20 2013 - Updated May 20 2013 - 1 reports

ImmunoCellular obtains US patent covering use of interleukin 13-receptor alpha 2 protein

ImmunoCellular Therapeutics has obtained US patent for methods of use of interleukin 13-receptor alpha 2 protein (IL-13Rα2) in cancer immunotherapy. ... [Published PBR - News - May 20 2013]

Entities: interleukin, Protein, Patent

First reported May 16 2013 - Updated May 16 2013 - 2 reports

ImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Cancer Vaccine Target

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. (âImmunoCellularâ) (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a patent covering methods of use of interleukin 13-receptor alpha 2 protein (IL-13RÎ±2) ... [Published Street Insider - May 16 2013]

Entities: ImmunoCellular Therapeutics, Patent, dendritic cell vaccine

First reported May 15 2013 - Updated May 15 2013 - 1 reports

American Apparel Inc

PENNY STOCK PERFORMERS: ImmunoCellular Therapeutics, Ltd., American Apparel Inc, Sirius XM Radio Inc., Growlife Inc

Huntington Beach, CA -- (SBWIRE) -- 05/15/2013 -- PSPicks.com provides its subscribers with a free newsletter that reports up to the minute information and exclusive charts on cheap, undervalued, hidden, and undiscovered stocks traded on the NASDAQ, ... [Published SBWire - May 15 2013]

Entities: ImmunoCellular Therapeutics, American Apparel Inc, SIRIUS XM Radio Inc

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Phase II

ImmunoCellular Therapeutics Reports First Quarter 2013 Financial Results

ImmunoCellular Therapeutics, Ltd. announced financial results for the quarter ended March 31. In a release on May 9, the Company noted earnings details:For the quarter ended March 31, the Company incurred a net loss of $5.0 million, or $0.10 per basic ... [Published Individual.com - May 14 2013]

Entities: ImmunoCellular Therapeutics, Phase II, Stocks

First reported May 10 2013 - Updated May 10 2013 - 1 reports

ImmunoCellular Therapeutics: Marching Toward Top Line Data For ICT-107 In Q4 2013

IntroductionThis note is based on comments made by management during the ImmunoCellular Therapeutics (IMUC) conference call of May 9, 2013.Data from the Phase II Trial of ICT-107ImmunoCellular continues to guide that the Data Monitoring Committee for ... [Published Seeking Alpha - May 10 2013]

Entities: Phase II, ImmunoCellular Therapeutics, Phase III, glioblastoma multiforme

First reported May 10 2013 - Updated May 10 2013 - 1 reports

New York Stock Exchange

ImmunoCellular Therapeutics, Ltd Announces First Quarter 2013 Financial Results

Staying up-to-date has never been simpler. Sign up for the today! . (âImmunoCellularâ) (NYSE MKT: IMUC) today announced financial results for the quarter ended March 31, 2013. For the quarter ended March 31, 2013, the Company incurred a net loss of $5.0 ... [Published BioSpace - May 10 2013]

Entities: ImmunoCellular Therapeutics, New York Stock Exchange

First reported May 10 2013 - Updated May 10 2013 - 1 reports

ImmunoCellular Therapeutics Ltd (IMUC) Posts Quarterly Earnings, Beats Expectations By $0.03 EPS

ImmunoCellular Therapeutics Ltd (NASDAQ: IMUC) announced its earnings results on Thursday. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.08) by $0.03, reports. On the ratings front, analysts at ... [Published American Banking News - May 10 2013]

Entities: ImmunoCellular Therapeutics, Therapeutics, Immune System

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Mentor Capital Reports First Quarter Results for Cancer Immunotherapy Index

Mentor Capital, Inc. reports that its proprietary Cancer Immunotherapy Index appreciated 28.0 percent during the first quarter of 2013. In a release on May 2, the Company noted the equally weighted Cancer Immunotherapy Index is regularly benchmarked against ... [Published Individual.com - May 07 2013]

Entities: Cancer Immunotherapy, Mentor Capital, Celldex Therapeutics Inc, Index, Vical Incorporated

First reported May 06 2013 - Updated May 06 2013 - 1 reports

ImmunoCellular Therapeutics Sets Date to Release 1Q 2013 Financial Results

ImmunoCellular Therapeutics has announced that it plans to report first quarter 2013 financial results on Thursday, May 9. In a release, the Company noted event details:ImmunoCellular will host a conference call and webcast to discuss financial results ... [Published Individual.com - May 06 2013]

Entities: ImmunoCellular Therapeutics, Teleconference, Investor Relations

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Mentor Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013

SAN DIEGO - (BUSINESS WIRE) - Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 28.0% during the first quarter of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked ... [Published NewsBlaze - May 02 2013]

Entities: Cancer Immunotherapy, Mentor Capital, Celldex Therapeutics Inc, Advaxis Inc, ImmunoCellular Therapeutics

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Biotechnology Roundup - Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Onyx Pharmaceuticals Inc. (ONXX), Gilead Sciences, Inc (NASDAQ:GILD), ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC)

Stamford, CT -- (SBWIRE) -- 05/01/2013 -- Jet Life Penny Stocks provides investors with the Best penny stock alerts on a regular basis. We will send you alerts through our Penny Stock Newsletters and offer you the tools to help you along the way with ... [Published SBWire - May 01 2013]

Entities: AVEO Pharmaceuticals Inc, ImmunoCellular Therapeutics, Gilead Sciences Inc, Onyx Pharmaceuticals Inc

First reported May 01 2013 - Updated May 01 2013 - 2 reports

IMMUNOCELLULAR THERAPEUTICS LTD: ImmunoCellular Therapeutics to Report Financial Results for the First Quarter 2013 May 9, 2013

ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that it plans to report first quarter 2013 financial results on Thursday, May 9, 2013. ImmunoCellular will host a conference call and webcast to discuss financial results ... [Published 4 Traders - May 01 2013]

Entities: ImmunoCellular Therapeutics, dendritic cell vaccine, Antigen

Quotes

More From BioPortfolio on "ImmunoCellular obtains US patent covering use of interleukin 13-receptor alpha 2 protein"

ImmunoCellular obtains US patent covering use of interleukin 13receptor alpha 2 protein [Published BioPortfolio - May 20 2013]

...assets, ICT-107 and ICT-140, and represents a valuable addition to our patent estate," said Andrew Gengos, ImmunoCellular Chief Executive Officer. "IL-13R?2 is a tumor-associated antigen present in the majority of brain cancers, and we believe that using an immunotherapeutic vaccine that targets this and other specific antigens as well as cancer stem cells to stimulate an immune response represents a promising anticancer approach."

IMMUNOCELLULAR THERAPEUTICS LTD: ImmunoCellular Therapeutics Announces Issuance of Key Patent Cov ... [Published 4 Traders - May 16 2013]

Commented Andrew Gengos, ImmunoCellular CEO: "We are pleased with our first quarter progress and believe we are on track to achieve our major goals for the year. We continue to anticipate that in the second quarter the Data Monitoring Committee (DMC) for the ICT-107 phase II trial will communicate its recommendation based on the interim safety and futility analysis. Assuming a favorable outcome, we anticipate completing the trial and having initial top-line results available by the end of this year. Our plans to initiate a phase IIa trial for ICT-140 in patients with ovarian cancer in the second half of 2013 are progressing. We are optimistic that the investigator-sponsored phase I trial for ICT-121 in patients with recurrent glioblastoma to be conducted by Cedars-Sinai Medical Center will begin before the end of the second quarter. We are excited by the prospect of having three novel clinical programs active later this year, and by the progress we are making in planning for the expansion of our clinical portfolio. The at-the-market financing facility we established is designed to enable operational flexibility, while minimizing dilution. 2013 is off to a strong start and we look forward to a highly productive year."

ImmunoCellular Therapeutics Reports First Quarter 2013 Financial Results [Published Individual.com - May 14 2013]

..."We believe the world needs a 'plug-and-play'TM method of creating vaccines," says Greffex Chief Scientific Officer Dr. Uwe D Staerz. "Speed as well as flexibility is needed for vaccine design to combat emerged infectious threats. We had already shown with an Anthrax vaccine that we can create ANY vaccine within one month."

H7N9: Greffex 'Beats the Clock' to Build the First Comprehensive H7N9 Vaccine [Published NewsBlaze - May 01 2013]

More Content

sort by: Date \| Relevance
3 Small Cap Cancer Stocks With Upcoming Catalysts [Published Seeking Alpha - 19 hours ago]
ImmunoCellular obtains US patent covering use o... [Published BioPortfolio - May 20 2013]
ImmunoCellular obtains US patent covering use o... [Published PBR - News - May 20 2013]
ImmunoCellular Therapeutics Announces Issuance ... [Published Street Insider - May 16 2013]
IMMUNOCELLULAR THERAPEUTICS LTD: ImmunoCellular... [Published 4 Traders - May 16 2013]
ImmunoCellular Therapeutics Announces Issuance ... [Published Business Wire - May 16 2013]
ImmunoCellular Therapeutics Announces Issuance ... [Published Business Wire Science: Science News - May 16 2013]
ImmunoCellular Therapeutics Announces Issuance ... [Published Business Wire Health News - May 16 2013]
PENNY STOCK PERFORMERS: ImmunoCellular Therapeu... [Published SBWire - May 15 2013]
3 Biotech Stocks With Potential [Published Seeking Alpha - May 14 2013]
ImmunoCellular Therapeutics Reports First Quart... [Published Individual.com - May 14 2013]
SmithOnStocks Opines On Recent Biotech News [Published Seeking Alpha - May 13 2013]
ImmunoCellular Therapeutics: Marching Toward To... [Published Seeking Alpha - May 10 2013]
ImmunoCellular Therapeutics, Ltd Announces Firs... [Published BioSpace - May 10 2013]
ImmunoCellular Therapeutics Ltd (IMUC) Posts Qu... [Published American Banking News - May 10 2013]
ImmunoCellular Therapeutics Announces First Qua... [Published Business Wire - May 09 2013]
ImmunoCellular Therapeutics Announces First Qua... [Published Business Wire Health News - May 09 2013]
Northwest Biotherapeutics: Moving DC Vax-L Rapi... [Published Seeking Alpha - May 08 2013]
Mentor Capital Reports First Quarter Results fo... [Published Individual.com - May 07 2013]
ImmunoCellular Therapeutics Sets Date to Releas... [Published Individual.com - May 06 2013]
Mentor Capital Cancer Immunotherapy Index Gains... [Published NewsBlaze - May 02 2013]
Mentor Capital Cancer Immunotherapy Index Gains... [Published EON Business - May 02 2013]
Mentor Capital Cancer Immunotherapy Index Gains... [Published EON Science - May 02 2013]
Mentor Capital Cancer Immunotherapy Index Gains... [Published Business Wire Professional Services News - May 02 2013]
It’s May Day, RegMeds of the world unite, you h... [Published Proactive Investors USA - May 01 2013]
With A New Institutional Investor On Board, Nor... [Published Seeking Alpha - May 01 2013]
Biotechnology Roundup - Aveo Pharmaceuticals In... [Published SBWire - May 01 2013]
H7N9: Greffex 'Beats the Clock' to Build the Fi... [Published NewsBlaze - May 01 2013]
IMMUNOCELLULAR THERAPEUTICS LTD: ImmunoCellular... [Published 4 Traders - May 01 2013]
ImmunoCellular Therapeutics to Report Financial... [Published OSIX News - May 01 2013]

Blogs

sort by: Date \| Relevance
ImmunoCellular obtains US patent covering use o... [Published PBR - News - May 20 2013] ImmunoCellular Therapeutics has obtained US patent for methods of use of interleukin 13-receptor alpha 2 protein (IL-13Rα2) in cancer immunotherapy. ...
ImmunoCellular appoints Gary S. Titus to board,... [Published Proactiveinvestors United Kingdom website - Jan 11 2013] ImmunoCellular Therapeutics (AMEX:IMUC) Wednesday announced the appointment of Gary S. Titus to its board of directors, sending shares up over five per cent. Shares of the company were higher by 10 cents as at about 1:45 p.m. EDT, trading at $2.02. ...
Up And Down The Ladder… Job Changes [Published Pharmalot - Dec 07 2012] Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them . Don’t be shy. Everyone wants ...
ImmunoCellular appoints new chief executive off... [Published PBR - News - Dec 04 2012] Clinical-stage company ImmunoCellular Therapeutics has named Andrew Gengos as the company's president, chief executive officer and board member. ...

Press Releases

sort by: Date \| Relevance
ImmunoCellular Therapeutics Announces Issuance ... [Published Business Wire - May 16 2013]
ImmunoCellular Therapeutics Announces Issuance ... [Published Business Wire Science: Science News - May 16 2013]
ImmunoCellular Therapeutics Announces Issuance ... [Published Business Wire Health News - May 16 2013]
ImmunoCellular Therapeutics Announces First Qua... [Published Business Wire - May 09 2013]
ImmunoCellular Therapeutics Announces First Qua... [Published Business Wire Health News - May 09 2013]